Health Care / Life Sciences

IRA Ventures invests in the next generation of pharmaceutical, biotechnology, medical device, diagnostics, and life science companies, with a focus on companies that drive innovation and increase patient access and provide quality outcomes.

Featured Transaction

  • ExThera Medical Corporation, founded in 2008 at the Karolinska Institute of Stockholm, is a developer and manufacturer of extracorporeal blood filtration devices.

  • ExThera's flagship product, the Seraph 100, is the first and only commercially available pathogen agnostic adsorption therapy that is CE marked for Europe and granted Emergency Use Authorization (EUA) for SARS-CoV-2 treatment in the United States by the FDA.

  • ExThera Medical's extracorporeal products have shown life-saving capabilities in a diverse range of critically ill patients with severe infections.

  • The company is well-equipped to serve both healthcare professionals and patients, thanks to a growing collection of outcome and health economic evidence from independent clinical studies, its involvement in the DARPA dialysis-like therapeutics program, and its successful clinical use in both the U.S. and EU.